Relay Therapeutics (RLAY)
(Real Time Quote from BATS)
$7.60 USD
-0.39 (-4.88%)
Updated Aug 2, 2024 10:46 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Relay Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 26 | 1 | 3 | 83 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 26 | 1 | 3 | 83 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 399 | 301 | 368 | 138 | 84 |
Income After Depreciation & Amortization | -373 | -299 | -365 | -56 | -84 |
Non-Operating Income | 31 | 9 | 1 | 3 | 9 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -342 | -291 | -364 | -52 | -75 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -342 | -291 | -364 | -52 | -75 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -342 | -291 | -364 | -52 | -75 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -378 | -294 | -359 | -53 | -84 |
Depreciation & Amortization (Cash Flow) | -5 | 5 | 6 | 3 | 0 |
Income After Depreciation & Amortization | -373 | -299 | -365 | -56 | -84 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 122.58 | 112.23 | 95.14 | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.79 | -2.69 | -2.70 | NA | NA |
Diluted Net EPS (GAAP) | -2.79 | -2.59 | -3.82 | -5.40 | NA |
Fiscal Year end for Relay Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 10.01 | 0.00 | 25.20 | 0.12 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 10.01 | 0.00 | 25.20 | 0.12 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 100.37 | 92.20 | 98.78 | 106.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -90.36 | -92.20 | -73.58 | -106.05 |
Non-Operating Income | NA | 8.98 | 8.70 | 7.84 | 7.55 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -81.39 | -83.50 | -65.73 | -98.51 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -81.39 | -83.50 | -65.73 | -98.51 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -81.39 | -83.49 | -65.73 | -98.51 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 130.84 | 124.75 | 122.23 | 121.68 |
Diluted EPS Before Non-Recurring Items | NA | -0.62 | -0.67 | -0.54 | -0.81 |
Diluted Net EPS (GAAP) | NA | -0.62 | -0.66 | -0.54 | -0.81 |